Drug Trial Radar · NCT07425392
Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
752
Actual
Start
Feb 9, 2026
Primary completion
Oct 25, 2026
Study completion Oct 25, 2026
Sponsor
- Lead sponsor
- Vaxcyte, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study will evaluate the safety, tolerability, and immunogenicity of VAX-31 in adults ≥50 years of age.
Conditions
- Pneumococcal Disease
Interventions
31-valent pneumococcal conjugate vaccineBiological
0.5 mL of VAX-31 will be administered into the deltoid muscle
PCV20Biological
0.5 mL of the 20-valent pneumococcal conjugate vaccine will be administered into the deltoid muscle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Serotype-specific OPA geometric mean titers (GMT)Time frame: 1 month after VAX-31 vaccination
- Serotype-specific OPA geometric mean fold rise (GMFR) from baselineTime frame: 1 month after VAX-31 vaccination
- Percentage of subjects reporting solicited local adverse events (AE) (redness, swelling, and pain at injection site)Time frame: up to 7 days after vaccination
- Percentage of subjects reporting solicited systemic AE (fever, headache, fatigue, muscle pain, and joint pain)Time frame: up to 7 days after vaccination
- Percentage of subjects reporting unsolicited AETime frame: up to 31 days after vaccination
- Percentage of subjects reporting new onset of chronic illness (NOCI), medically attended AE (MAAE), and serious adverse events (SAE)Time frame: up to 6 months after vaccination
Locations
30 sites in 1 country. Site status is shown where the registry gives one.
Chinle Center for Indigenous Health
Chinle, Arizona
Avacare (CCT Research)
Phoenix, Arizona
Whiteriver Center for Indigenous Health
Whiteriver, Arizona
Chase Medical Research
Waterbury, Connecticut
CenExel (RCA)
Hollywood, Florida
Eximia (Health Awareness)
Jupiter, Florida
Eximia (Health Awareness)
Port Saint Lucie, Florida
Precision Clinical Research
Sunrise, Florida
The Villages
The Villages, Florida
DelRicht Clinical Research
Stockbridge, Georgia
Velocity Clinical Valparaiso
Valparaiso, Indiana
Johnson County Clin-Trials, LLC
Lenexa, Kansas
DelRicht Clinical Research
New Orleans, Louisiana
Velocity (Meridian Clinical Research)
Rockville, Maryland
DM Clinical Research-Detroit
Southfield, Michigan
AMR
Kansas City, Missouri
DelRicht Research (Command Family Medicine)
Springfield, Missouri
Quality Clinical Research
Omaha, Nebraska
Center of American Indian Health
Gallup, New Mexico
Shiprock Center for Indigenous Health
Shiprock, New Mexico
Rochester Clinical Research, Inc.
Rochester, New York
Headlands (Trial Management Associates)
Wilmington, North Carolina
Tekton Research
Edmond, Oklahoma
DelRicht Research
Hendersonville, Tennessee
Tekton Research
Austin, Texas
REX Clinical Trials
Beaumont, Texas
Flourish Research
San Antonio, Texas
DM Clinical Research
Sugar Land, Texas
Alcanza (Charlottesville Medical Research)
Charlottesville, Virginia
Health Research of Hampton Roads, Inc.
Newport News, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.